Page 21 - IMO-2-1

Innovative Medicines & Omics Incretin mimetics in diabetes management

in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S111-S124. 38. Teague M, Martinez A, Walker E, El-Rifai M, Carris NW.
Use and interchange of incretin mimetics in the treatment
doi: 10.2337/dc21-S009
of metabolic diseases: A narrative review. Clin Ther.
28. Michałowska J, Miller-Kasprzak E, Bogdański P. Incretin 2023;45(3):248-261.
hormones in obesity and related cardiometabolic disorders:
The clinical perspective. Nutrients. 2021;13(2):351. doi: 10.1016/j.clinthera.2023.02.003
doi: 10.3390/nu13020351 39. Dalle S, Abderrahmani A. Receptors and signaling pathways
controlling beta-cell function and survival as targets for
29. Zhong J, Chen H, Liu Q, Zhou S, Liu Z, Xiao Y. GLP-1 anti-diabetic therapeutic strategies. Cells. 2024;13(15):1244.
receptor agonists and myocardial metabolism in atrial
fibrillation. J Pharm Anal. 2024;14(5):100917. doi: 10.3390/cells13151244
doi: 10.1016/j.jpha.2023.12.007 40. Furman BL. The development of Byetta (exenatide) from
the venom of the Gila monster as an anti-diabetic agent.
30. Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA. Toxicon. 2012;59(4):464-471.
Occurrence of nausea, vomiting and diarrhoea reported
as adverse events in clinical trials studying glucagon- doi: 10.1016/j.toxicon.2010.12.016
like peptide-1 receptor agonists: A systematic analysis 41. Mann KV, Raskin P. Exenatide extended-release: A once
of published clinical trials. Diabetes Obes Metab. weekly treatment for patients with type 2 diabetes. Diabetes
2017;19(3):336-347. Metab Syndr Obes. 2014;7:229-239.
doi: 10.1111/dom.12824 doi: 10.2147/DMSO.S35331
31. Gilbert MP, Pratley RE. GLP-1 analogs and DPP-4 inhibitors 42. van der Aart-van der Beek AB, van Raalte DH, Guja C, et al.
in type 2 diabetes therapy: Review of head-to-head clinical Exenatide once weekly decreases urinary albumin excretion
trials. Front Endocrinol (Lausanne). 2020;11:178. in patients with type 2 diabetes and elevated albuminuria:
doi: 10.3389/fendo.2020.00178 Pooled analysis of randomized active controlled clinical
trials. Diabetes Obes Metab. 2020;22(9):1556-1566.
32. Ma X, Liu Z, Ilyas I, et al. GLP-1 receptor agonists (GLP-
1RAs): Cardiovascular actions and therapeutic potential. Int doi: 10.1111/dom.14067
J Biol Sci. 2021;17(8):2050-2068.
43. Mehta A, Marso SP, Neeland IJ. Liraglutide for weight
doi: 10.7150/ijbs.59965 management: A critical review of the evidence. Obes Sci
Pract. 2017;3(1):3-14.
33. Winiarska A, Knysak M, Nabrdalik K, Gumprecht J,
Stompór T. Inflammation and oxidative stress in diabetic doi: 10.1002/osp4.84
kidney disease: The targets for SGLT2 inhibitors and GLP-1 44. Li Z, Ni CL, Yao Z, Chen LM, Niu WY. Liraglutide enhances
receptor agonists. Int J Mol Sci. 2021;22(19):10822.
glucose transporter 4 translocation via regulation of AMP-
doi: 10.3390/ijms221910822 activated protein kinase signaling pathways in mouse
34. Jensen JK, Binderup T, Grandjean CE, Bentsen S, skeletal muscle cells. Metabolism. 2014;63(8):1022-1030.
Ripa RS, Kjaer A. Semaglutide reduces vascular doi: 10.1016/j.metabol.2014.05.008
inflammation investigated by PET in a rabbit model of
advanced atherosclerosis. Atherosclerosis. 2022;352:88-95. 45. Zobel EH, Ripa RS, Von Scholten BJ, et al. Effect of liraglutide
on expression of inflammatory genes in type 2 diabetes. Sci
doi: 10.1016/j.atherosclerosis.2022.03.032 Rep. 11(1):18522.
35. Greco EV, Russo G, Giandalia A, Viazzi F, Pontremoli R, De doi: 10.1038/s41598-021-97967-0
Cosmo S. GLP-1 receptor agonists and kidney protection.
Medicina (Kaunas). 2019;55(6):233. 46. Wronka M, Krzemińska J, Młynarska E, Rysz J,
Franczyk B. New insights into the use of liraglutide-
doi: 10.3390/medicina55060233 impact on cardiovascular risk and microvascular outcomes.
36. Rolek B, Haber M, Gajewska M, Rogula S, Pietrasik A, Biomedicines. 2023;11(4):1159.
Gąsecka A. SGLT2 inhibitors vs. GLP-1 agonists to treat doi: 10.3390/biomedicines1104115
the heart, the kidneys and the brain. J Cardiovasc Dev Dis.
2023;10(8):322. 47. Frandsen CS, Dejgaard TF, Andersen HU, et al. Liraglutide
as adjunct to insulin treatment in type 1 diabetes does not
doi: 10.3390/jcdd10080322 interfere with glycaemic recovery or gastric emptying rate
37. Mariam Z, Niazi SK. Glucagon-like peptide agonists: during hypoglycaemia: A randomized, placebo-controlled,
A prospective review. Endocrinol Diabetes Metab. double-blind, parallel-group study. Diabetes Obes Metab.
2024;7(1):e462. 2017;19(6):773-782.
doi: 10.1002/edm2.462 doi: 10.1111/dom.12830

Volume 2 Issue 1 (2025) 15 doi: 10.36922/imo.4911